Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology-Reference-Cited by-同舟云学术

Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology

Published:2012-05 Issue:7 Volume:48 Page:1038-1047
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Gore M.E.,Bellmunt J.,Eisen T.,Escudier B.,Mickisch G.,Patard J.,Porta C.,Ravaud A.,Schmidinger M.,Schöffski P.,Sternberg C.N.,Szczylik C.,De Nigris E.,Wheeler C.,Kirpekar S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference73 articles.

1. Metastatic renal cell carcinoma: many treatment options, one patient;Rini;J Clin Oncol,2009

2. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2009

3. EAU guidelines on renal cell carcinoma: the 2010 update;Ljungberg;Eur Urol,2010

4. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel;Halbert;Cancer,2006

5. Fitch K, et al. The RAND/UCLA Appropriateness Method User’s Manual. Rand Corporation, 2001.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial Intelligence;Clinical Applications of Artificial Intelligence in Real-World Data;2023

2. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment—Analyses from the German clinical RCC-Registry;Urologic Oncology: Seminars and Original Investigations;2018-10

3. Consensus guidelines on the optimal management in interventional EUS procedures: results from the Asian EUS group RAND/UCLA expert panel;Gut;2018-02-20

4. Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib;American Journal of Clinical Oncology;2017-02

5. Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma;Future Oncology;2017-01